Around 36% of employers said they provide coverage of GLP-1s for both diabetes and weight loss, the same percentage as 2025 and up from 34% in 2024, the survey said
Liu B, Yu Y, Liu W, Deng T, Xiang D
The primary justification is the presence of a drug on the FDAs official drug shortage list
Molecular dynamics studies Molecular Dynamics (MD) simulations were performed for the apo AlphaFold prepared structure of SLC25A45, as well as when in complex/docked to the ligand TML
It directly stimulates pro-opiomelanocortin/cocaine-and-amphetamine-regulated transcript (POMC/CART) neurons and indirectly inhibits neuropeptide-Y/agouti-related protein (NPY/AgRP) neurons through GABA neurotransmission, reducing appetite and promoting weight loss [40]
doi: 10.4140/TCP.n.2016.685 38 WaddenTATronieriJSSugimotoDLundMTAuerbachPJensenCet al